-
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement. Endocr. Rev. (IF 22.0) Pub Date : 2024-10-23 Niki Karavitaki,Jeffrey J Bettinger,Nienke Biermasz,Mirjam Christ-Crain,Monica R Gadelha,Warrick J Inder,Elena Tsourdi,Sarah E Wakeman,Maria Zatelli
The use and misuse of opioids are a growing global problem. Although the effects of these drugs on the human endocrine system have been studied for decades, attention on their related clinical consequences, particularly on the hypothalamic-pituitary system and bone health, has intensified over recent years. This Statement appraises research data related to the impact of opioids on the gonadal and adrenal
-
The Insulin-like Growth Factor System and Aging. Endocr. Rev. (IF 22.0) Pub Date : 2024-10-17 Cheryl A Conover,Claus Oxvig
There is strong evidence that insulin-like growth factor (IGF) signaling is involved in fundamental aspects of the aging process. However, the extracellular part of the IGF system is complex with various receptors, ligand effectors, high affinity IGF binding proteins, proteinases and endogenous inhibitors that all, along with their biological context, must be considered. The IGF system components are
-
Papillary Craniopharyngioma: an integrative and comprehensive review. Endocr. Rev. (IF 22.0) Pub Date : 2024-10-01 Ruth Prieto,Tareq A Juratli,Evan D Bander,Sandro Santagata,Laura Barrios,Priscilla K Brastianos,Theodore H Schwartz,José M Pascual
Papillary craniopharyngioma (PCP) is a rare type of tumor, comprising ∼20% of all craniopharyngioma (CP) cases. It is now recognized as a separate pathological entity from the adamantinomatous type. PCPs are benign tumors, classified as WHO grade 1, characterized by non-keratinizing squamous epithelium. They typically grow as solid and round papillomatous masses or as unilocular cysts with a cauliflower-like
-
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-06 Robert Krysiak,Hedi L Claahsen-van der Grinten,Nicole Reisch,Philippe Touraine,Henrik Falhammar
Treatment of classic congenital adrenal hyperplasia (CAH) is directed at replacing deficient hormones and reducing androgen excess. However, even in the era of early diagnosis and lifelong hormonal substitution, the presence of CAH is still associated with numerous complications and also with increased mortality. The aim of this article was to create an authoritative and balanced review concerning
-
Postbiotic impact on host metabolism and immunity provides therapeutic potential in metabolic disease. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-05 Han Fang,Rodrigo Rodrigues E-Lacerda,Nicole G Barra,Dana Kukje Zada,Nazli Robin,Alina Mehra,Jonathan D Schertzer
The gut microbiota influences aspects of metabolic disease, including tissue inflammation, adiposity, blood glucose, insulin, and endocrine control of metabolism. Prebiotics or probiotics are often sought to combat metabolic disease. However, prebiotics lack specificity and can have deleterious bacterial community effects. Probiotics require live bacteria to find a colonization niche sufficient to
-
The cortisol awakening response: regulation and functional significance. Endocr. Rev. (IF 22.0) Pub Date : 2024-08-23 Tobias Stalder,Henrik Oster,James L Abelson,Katharina Huthsteiner,Tim Klucken,Angela Clow
In healthy individuals, the majority of cortisol secretion occurs within several hours surrounding morning awakening. A highly studied component of this secretory period is the cortisol awakening response (CAR), the rapid increase in cortisol levels across the first 30-45 min after morning awakening. This strong cortisol burst at the start of the active phase has been proposed to be functional in preparing
-
Structure and Function of Somatostatin and its Receptors in Endocrinology. Endocr. Rev. (IF 22.0) Pub Date : 2024-08-08 Bo Zhang,Li Xue,Zhe Bao Wu
Somatostatin analogs, such as octreotide (OCT), lanreotide, and pasireotide, which function as somatostatin receptor ligands (SRLs), are the main drugs used for the treatment of acromegaly. These ligands are also used as important molecules for radiation therapy and imaging of neuroendocrine tumors (NETs). Somatostatin receptors (SSTRs) are canonical G protein-coupled proteins (GPCRs) that play a role
-
Adiponectin and Adiponectin Receptors in Atherosclerosis. Endocr. Rev. (IF 22.0) Pub Date : 2024-08-06 Ioanna Gianopoulos,Christos S Mantzoros,Stella S Daskalopoulou
Adiponectin is an abundantly secreted hormone that communicates information between the adipose tissue, and the immune and cardiovascular systems. In metabolically healthy individuals, adiponectin is usually found at high levels and helps improve insulin responsiveness of peripheral tissues, glucose tolerance, and fatty acid oxidation. Beyond its metabolic functions in insulin-sensitive tissues, adiponectin
-
Molecular developments in parasellar tumors and potential therapeutic implications. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-26 Paraskevi Xekouki,Vasiliki Venetsanaki,Georgios Kyriakopoulos,Krystallenia Alexandraki,Anna Angelousi,Gregory Kaltsas
The parasellar region is the anatomical area around the sella turcica that represents a crucial crossroad for important adjacent structures. Several distinct tumors can primarily originate from this area, the most common being meningiomas, gliomas, embryonal cell tumors, germ cell tumors and craniopharyngiomas. In addition, a number of systemic and inflammatory disorders can also affect the parasellar
-
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Jack Lockett,Warrick J Inder,Vicki L Clifton
Glucocorticoids exert pleiotropic effects on all tissues to regulate cellular and metabolic homeostasis. Synthetic forms are used therapeutically in a wide range of conditions for their anti-inflammatory benefits, at the cost of dose and duration-dependent side effects. Significant variability occurs between tissues, disease states, and individuals with regard to both the beneficial and deleterious
-
The Search for the Causes of Common Hyperandrogenism, 1965 to Circa 2015. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Robert L Rosenfield
From 1965 to 2015, immense strides were made into understanding the mechanisms underlying the common androgen excess disorders, premature adrenarche and polycystic ovary syndrome (PCOS). The author reviews the critical discoveries of this era from his perspective investigating these disorders, commencing with his early discoveries of the unique pattern of plasma androgens in premature adrenarche and
-
Mini-Puberty, Physiological and Disordered: Consequences, and Potential for Therapeutic Replacement. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Julia Rohayem,Emma C Alexander,Sabine Heger,Anna Nordenström,Sasha R Howard
There are 3 physiological waves of central hypothalamic-pituitary-gonadal (HPG) axis activity over the lifetime. The first occurs during fetal life, the second-termed "mini-puberty"-in the first months after birth, and the third at puberty. After adolescence, the axis remains active all through adulthood. Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic disorder characterized by a deficiency
-
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Ondrej Uher,Katerina Hadrava Vanova,David Taïeb,Bruna Calsina,Mercedes Robledo,Roderick Clifton-Bligh,Karel Pacak
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from neural crest cells from adrenal medullary chromaffin tissues and extra-adrenal paraganglia, respectively. Although the current treatment for PPGLs is surgery, optimal treatment options for advanced and metastatic cases have been limited. Hence, understanding the role of the immune system in PPGL tumorigenesis can
-
Preclinical Rodent Models for Human Bone Disease, Including a Focus on Cortical Bone. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Natalie Y Y Koh,Justyna J Miszkiewicz,Mary Louise Fac,Natalie K Y Wee,Natalie A Sims
Preclinical models (typically ovariectomized rats and genetically altered mice) have underpinned much of what we know about skeletal biology. They have been pivotal for developing therapies for osteoporosis and monogenic skeletal conditions, including osteogenesis imperfecta, achondroplasia, hypophosphatasia, and craniodysplasias. Further therapeutic advances, particularly to improve cortical strength
-
Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome. Endocr. Rev. (IF 22.0) Pub Date : 2024-07-12 Yi Chen,Guiquan Wang,Jingqiao Chen,Congying Wang,Xi Dong,Hsun-Ming Chang,Shuai Yuan,Yue Zhao,Liangshan Mu
The treatment of polycystic ovary syndrome (PCOS) faces challenges as all known treatments are merely symptomatic. The US Food and Drug Administration has not approved any drug specifically for treating PCOS. As the significance of genetics and epigenetics rises in drug development, their pivotal insights have greatly enhanced the efficacy and success of drug target discovery and validation, offering
-
Common and uncommon mouse models of growth hormone deficiency. Endocr. Rev. (IF 22.0) Pub Date : 2024-06-10 Edward O List,Reetobrata Basu,Darlene E Berryman,Silvana Duran-Ortiz,Gabriel Á Martos-Moreno,John J Kopchick
Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the five "common" mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased
-
Teprotumumab for the treatment of Thyroid eye disease. Endocr. Rev. (IF 22.0) Pub Date : 2024-06-05 Shoaib Ugradar,Emil Malkhasyan,Raymond S Douglas
Thyroid eye disease (TED) is the most common extra thyroidal manifestation of Graves' disease (GD). It may also present in those who are hypothyroid or euthyroid. The characteristic clinical manifestations of TED: chemosis, lid swelling, proptosis and diplopia are driven by a combination of inflammation and extracellular matrix modification. It has recently emerged that one of the major drivers of
-
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-25 Sophie A Clarke,Pei Chia Eng,Alexander N Comninos,Katharine Lazarus,Sirazum Choudhury,Christie Tsang,Karim Meeran,Tricia M Tan,Waljit S Dhillo,Ali Abbara
Glucocorticoid hormones (GC) are secreted in a circadian and ultradian rhythm and play a critical role in maintaining physiological homeostasis, with both excess and insufficient GC associated with adverse effects on health. Current assessment of GC status is primarily clinical, often in conjunction with serum cortisol values, which may be stimulated or suppressed depending on the GC disturbance being
-
Phosphorylation-Dependent Regulation of Guanylyl Cyclase (GC)-A and Other Membrane GC Receptors. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-12 Lincoln R Potter
Receptor guanylyl cyclases (GCs) are single membrane spanning, multidomain enzymes, that synthesize cGMP in response to natriuretic peptides or other ligands. They are evolutionarily conserved from sea urchins to humans and regulate diverse physiologies. Most family members are phosphorylated on 4 to 7 conserved serines or threonines at the beginning of their kinase homology domains. This review describes
-
Correction to: "The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa". Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07
-
Correction to: "ER Stress in Cardiometabolic Diseases: From Molecular Mechanisms to Therapeutics". Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07
-
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07 Julio Rosenstock,Rattan Juneja,John M Beals,Julie S Moyers,Liza Ilag,Rory J McCrimmon
Basal insulin continues to be a vital part of therapy for many people with diabetes. First attempts to prolong the duration of insulin formulations were through the development of suspensions that required homogenization prior to injection. These insulins, which required once- or twice-daily injections, introduced wide variations in insulin exposure contributing to unpredictable effects on glycemia
-
The Molecular Biology of Midgut Neuroendocrine Neoplasms. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07 Amy P Webster,Chrissie Thirlwell
Midgut neuroendocrine neoplasms (NENs) are one of the most common subtypes of NEN, and their incidence is rising globally. Despite being the most frequently diagnosed malignancy of the small intestine, little is known about their underlying molecular biology. Their unusually low mutational burden compared to other solid tumors and the unexplained occurrence of multifocal tumors makes the molecular
-
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07 Kim Henriksen,Federica Genovese,Alexander Reese-Petersen,Laurent P Audoly,Kai Sun,Morten A Karsdal,Philipp E Scherer
Our overview covers several key areas related to recent results obtained for collagen type VI and endotrophin (ETP). (1) An introduction to the history of ETP, including how it was identified, how it is released, and its function and potential receptors. (2) An introduction to the collagen family, with a focus on what differentiates collagen type VI from an evolutionary standpoint. (3) An overview
-
The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-02 Adrian F Daly,Albert Beckers
Pituitary gigantism is a rare manifestation of chronic growth hormone (GH) excess that begins before closure of the growth plates. Nearly half of pituitary gigantism patients have an identifiable genetic cause. X-linked acrogigantism (X-LAG; 10% of pituitary gigantism) typically begins during infancy and can lead to the tallest individuals described. In the 10 years since its discovery, about 40 patients
-
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-12 Andrea Giustina,John P Bilezikian,Robert A Adler,Giuseppe Banfi,Daniel D Bikle,Neil C Binkley,Jens Bollerslev,Roger Bouillon,Maria Luisa Brandi,Felipe F Casanueva,Luigi di Filippo,Lorenzo M Donini,Peter R Ebeling,Ghada El-Hajj Fuleihan,Angelo Fassio,Stefano Frara,Glenville Jones,Claudio Marcocci,Adrian R Martineau,Salvatore Minisola,Nicola Napoli,Massimo Procopio,René Rizzoli,Anne L Schafer,Christopher
The 6th International Conference, "Controversies in Vitamin D," was convened to discuss controversial topics, such as vitamin D metabolism, assessment, actions, and supplementation. Novel insights into vitamin D mechanisms of action suggest links with conditions that do not depend only on reduced solar exposure or diet intake and that can be detected with distinctive noncanonical vitamin D metabolites
-
Towards a Robust Definition of Sport Sex. Endocr. Rev. (IF 22.0) Pub Date : 2024-04-05 David J Handelsman
Elite individual sports in which success depends on power, speed or endurance are conventionally divided into male and female events using traditional binary definitions of sex. Male puberty creates durable physical advantages due to the 20-30-fold increase in circulating testosterone producing a sustained uplift in men's muscle, bone, hemoglobin, and cardiorespiratory function resulting from male
-
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction. Endocr. Rev. (IF 22.0) Pub Date : 2024-09-12 Masayoshi Suda,Karl H Paul,Utkarsh Tripathi,Tohru Minamino,Tamara Tchkonia,James L Kirkland
Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological
-
Relative Energy Deficiency in sport (REDs): Endocrine manifestations, pathophysiology and treatments. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-15 Angeliki M Angelidi,Konstantinos Stefanakis,Sharon H Chou,Laura Valenzuela-Vallejo,Konstantina Dipla,Chrysoula Boutari,Konstantinos Ntoskas,Panagiotis Tokmakidis,Alexander Kokkinos,Dimitrios G Goulis,Helen A Papadaki,Christos S Mantzoros
Research on lean, energy-deficient athletic and military cohorts has broadened the concept of the Female Athlete Triad into the Relative Energy Deficiency in Sport (REDs) syndrome. REDs represents a spectrum of abnormalities induced by low energy availability (LEA), which serves as the underlying cause of all symptoms described within the REDs concept, affecting exercising populations of either biological
-
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07 Merijn C F Mulders,Wouter W de Herder,Johannes Hofland
Carcinoid syndrome (CS) is a debilitating disease that affects approximately 20% of patients with neuroendocrine neoplasms (NEN). Due to the increasing incidence and improved overall survival of patients with NEN over recent decades, patients are increasingly suffering from chronic and refractory CS symptoms. At present, symptom control is hampered by an incomplete understanding of the pathophysiology
-
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity. Endocr. Rev. (IF 22.0) Pub Date : 2024-05-07 Hoong-Wei Gan,Manuela Cerbone,Mehul Tulsidas Dattani
Since hypothalamic obesity (HyOb) was first described over 120 years ago by Joseph Babinski and Alfred Fröhlich, advances in molecular genetic laboratory techniques have allowed us to elucidate various components of the intricate neurocircuitry governing appetite and weight regulation connecting the hypothalamus, pituitary gland, brainstem, adipose tissue, pancreas, and gastrointestinal tract. On a
-
Update on Adipose Tissue and Cancer. Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Kristy A Brown,Philipp E Scherer
Adipose tissue is the largest endocrine organ and an accepted contributor to overall energy homeostasis. There is strong evidence linking increased adiposity to the development of 13 types of cancer. With increased adiposity comes metabolic dysfunction and insulin resistance, and increased systemic insulin and glucose support the growth of many cancers, including those of the colon and endometrium
-
Diabetes Mellitus, Energy Metabolism, and COVID-19. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-04 Caterina Conte,Elisa Cipponeri,Michael Roden
Obesity, diabetes mellitus (mostly type 2), and COVID-19 show mutual interactions because they are not only risk factors for both acute and chronic COVID-19 manifestations, but also because COVID-19 alters energy metabolism. Such metabolic alterations can lead to dysglycemia and long-lasting effects. Thus, the COVID-19 pandemic has the potential for a further rise of the diabetes pandemic. This review
-
Neurodevelopmental Programming of Adiposity: Contributions to Obesity Risk. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-04 Alicja A Skowronski,Rudolph L Leibel,Charles A LeDuc
This review analyzes the published evidence regarding maternal factors that influence the developmental programming of long-term adiposity in humans and animals via the central nervous system (CNS). We describe the physiological outcomes of perinatal underfeeding and overfeeding and explore potential mechanisms that may mediate the impact of such exposures on the development of feeding circuits within
-
Protective Factors and the Pathogenesis of Complications in Diabetes. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-04 Marc Gregory Yu,Daniel Gordin,Jialin Fu,Kyoungmin Park,Qian Li,George Liang King
Chronic complications of diabetes are due to myriad disorders of numerous metabolic pathways that are responsible for most of the morbidity and mortality associated with the disease. Traditionally, diabetes complications are divided into those of microvascular and macrovascular origin. We suggest revising this antiquated classification into diabetes complications of vascular, parenchymal, and hybrid
-
Metformin, Cognitive Function, and Changes in the Gut Microbiome. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-04 Marisel Rosell-Díaz,José Manuel Fernández-Real
The decline in cognitive function and the prevalence of neurodegenerative disorders are among the most serious threats to health in old age. The prevalence of dementia has reached 50 million people worldwide and has become a major public health problem. The causes of age-related cognitive impairment are multiple, complex, and difficult to determine. However, type 2 diabetes (T2D) is linked to an enhanced
-
Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV. Endocr. Rev. (IF 22.0) Pub Date : 2024-03-04 Claudia E Ramirez Bustamante,Neeti Agarwal,Aaron R Cox,Sean M Hartig,Jordan E Lake,Ashok Balasubramanyam
Over the past 4 decades, the clinical care of people living with HIV (PLWH) evolved from treatment of acute opportunistic infections to the management of chronic, noncommunicable comorbidities. Concurrently, our understanding of adipose tissue function matured to acknowledge its important endocrine contributions to energy balance. PLWH experience changes in the mass and composition of adipose tissue
-
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks. Endocr. Rev. (IF 22.0) Pub Date : 2024-01-04 Nathan Mullen,James Curneen,Padraig T Donlon,Punit Prakash,Irina Bancos,Mark Gurnell,Michael C Dennedy
Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure-matched cases of primary hypertension. Current limitations in patient care stem from delayed recognition of the condition, limited access to key diagnostic procedures, and lack of a definitive therapy option for nonsurgical candidates
-
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B. Endocr. Rev. (IF 22.0) Pub Date : 2024-01-04 Bijal Patel,Kanyada Koysombat,Edouard G Mills,Jovanna Tsoutsouki,Alexander N Comninos,Ali Abbara,Waljit S Dhillo
Kisspeptin (KP) and neurokinin B (NKB) are neuropeptides that govern the reproductive endocrine axis through regulating hypothalamic gonadotropin-releasing hormone (GnRH) neuronal activity and pulsatile GnRH secretion. Their critical role in reproductive health was first identified after inactivating variants in genes encoding for KP or NKB signaling were shown to result in congenital hypogonadotropic
-
Crosstalk Between the Neuroendocrine System and Bone Homeostasis. Endocr. Rev. (IF 22.0) Pub Date : 2024-01-04 Yuhu Zhao,Xiaole Peng,Qing Wang,Zhiyu Zhang,Liangliang Wang,Yaozeng Xu,Huilin Yang,Jiaxiang Bai,Dechun Geng
The homeostasis of bone microenvironment is the foundation of bone health and comprises 2 concerted events: bone formation by osteoblasts and bone resorption by osteoclasts. In the early 21st century, leptin, an adipocytes-derived hormone, was found to affect bone homeostasis through hypothalamic relay and the sympathetic nervous system, involving neurotransmitters like serotonin and norepinephrine
-
Biomarkers to Guide Medical Therapy in Primary Aldosteronism. Endocr. Rev. (IF 22.0) Pub Date : 2024-01-04 Gregory L Hundemer,Alexander A Leung,Gregory A Kline,Jenifer M Brown,Adina F Turcu,Anand Vaidya
Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated aldosterone production that occurs despite suppression of renin and angiotensin II, and that is non-suppressible by volume and sodium loading. The effectiveness of surgical adrenalectomy for patients with lateralizing PA is characterized by the attenuation of excess aldosterone production leading to blood pressure reduction
-
Intracellular to Interorgan Mitochondrial Communication in Striated Muscle in Health and Disease. Endocr. Rev. (IF 22.0) Pub Date : 2023-07-11 Neoma T Boardman,Giulia Trani,Marco Scalabrin,Vanina Romanello,Rob C I Wüst
Mitochondria sense both biochemical and energetic input in addition to communicating signals regarding the energetic state of the cell. Increasingly, these signaling organelles are recognized as key for regulating different cell functions. This review summarizes recent advances in mitochondrial communication in striated muscle, with specific focus on the processes by which mitochondria communicate
-
The Hypothalamus-pituitary-adrenocortical Response to Critical Illness: A Concept in Need of Revision. Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Lies Langouche,Arno Téblick,Jan Gunst,Greet Van den Berghe
Based on insights obtained during the past decade, the classical concept of an activated hypothalamus-pituitary-adrenocortical axis in response to critical illness is in need of revision. After a brief central hypothalamus-pituitary-adrenocortical axis activation, the vital maintenance of increased systemic cortisol availability and action in response to critical illness is predominantly driven by
-
Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics. Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Ryan M Marquardt,Dinh Nam Tran,Bruce A Lessey,Md Saidur Rahman,Jae-Wook Jeong
Endometriosis is a prevalent gynecological condition associated with pelvic pain and infertility. Despite more than a century of research, the etiology of endometriosis still eludes scientific consensus. This lack of clarity has resulted in suboptimal prevention, diagnosis, and treatment options. Evidence of genetic contributors to endometriosis is interesting but limited; however, significant progress
-
Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Shalender Bhasin,Douglas Seals,Marie Migaud,Nicolas Musi,Joseph A Baur
Recent research has unveiled an expansive role of NAD+ in cellular energy generation, redox reactions, and as a substrate or cosubstrate in signaling pathways that regulate health span and aging. This review provides a critical appraisal of the clinical pharmacology and the preclinical and clinical evidence for therapeutic effects of NAD+ precursors for age-related conditions, with a particular focus
-
The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story. Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Cheryl A Conover,Claus Oxvig
Pregnancy-associated plasma protein-A (PAPP-A) was first identified in the early 1970s as a placental protein of unknown function, present at high concentrations in the circulation of pregnant women. In the mid-to-late 1990s, PAPP-A was discovered to be a metzincin metalloproteinase, expressed by many nonplacental cells, that regulates local insulin-like growth factor (IGF) activity through cleavage
-
Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective? Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Laura J Mauro,Angela Spartz,Julia R Austin,Carol A Lange
Ovarian cancer (OC) represents a collection of rare but lethal gynecologic cancers where the difficulty of early detection due to an often-subtle range of abdominal symptoms contributes to high fatality rates. With the exception of BRCA1/2 mutation carriers, OC most often manifests as a post-menopausal disease, a time in which the ovaries regress and circulating reproductive hormones diminish. Progesterone
-
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocr. Rev. (IF 22.0) Pub Date : 2023-11-09 Riccardo Pofi,Giorgio Caratti,David W Ray,Jeremy W Tomlinson
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver therapeutic benefit is not in doubt. However, the side effects associated with their use, including central weight gain, hypertension, insulin resistance, type 2 diabetes (T2D), and osteoporosis, often collectively termed
-
Current and Future Advances in Surgical Therapy for Pituitary Adenoma. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Danyal Z Khan,John G Hanrahan,Stephanie E Baldeweg,Neil L Dorward,Danail Stoyanov,Hani J Marcus
The vital physiological role of the pituitary gland, alongside its proximity to critical neurovascular structures, means that pituitary adenomas can cause significant morbidity or mortality. While enormous advancements have been made in the surgical care of pituitary adenomas, numerous challenges remain, such as treatment failure and recurrence. To meet these clinical challenges, there has been an
-
Medullary Thyroid Cancer: Updates and Challenges. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Matti L Gild,Roderick J Clifton-Bligh,Lori J Wirth,Bruce G Robinson
A personalized approach to the management of medullary thyroid cancer (MTC) presents several challenges; however, in the past decade significant progress has been made in both diagnostic and treatment modalities. Germline rearranged in transfection (RET) testing in multiple endocrine neoplasia 2 and 3, and somatic RET testing in sporadic MTC have revolutionized the treatment options available to patients
-
AMPK and the Endocrine Control of Metabolism. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Logan K Townsend,Gregory R Steinberg
Complex multicellular organisms require a coordinated response from multiple tissues to maintain whole-body homeostasis in the face of energetic stressors such as fasting, cold, and exercise. It is also essential that energy is stored efficiently with feeding and the chronic nutrient surplus that occurs with obesity. Mammals have adapted several endocrine signals that regulate metabolism in response
-
Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Graeme Eisenhofer,Christina Pamporaki,Jacques W M Lenders
Pheochromocytoma and paraganglioma (PPGL) require prompt consideration and efficient diagnosis and treatment to minimize associated morbidity and mortality. Once considered, appropriate biochemical testing is key to diagnosis. Advances in understanding catecholamine metabolism have clarified why measurements of the O-methylated catecholamine metabolites rather than the catecholamines themselves are
-
Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Annabelle M Warren,Mathis Grossmann,Mirjam Christ-Crain,Nicholas Russell
Hyponatremia is the most common electrolyte disorder, affecting more than 15% of patients in the hospital. Syndrome of inappropriate antidiuresis (SIAD) is the most frequent cause of hypotonic hyponatremia, mediated by nonosmotic release of arginine vasopressin (AVP, previously known as antidiuretic hormone), which acts on the renal V2 receptors to promote water retention. There are a variety of underlying
-
Signaling Pathways of the Insulin-like Growth Factor Binding Proteins. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Robert C Baxter
The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) are multifunctional proteins that modulate cell signaling through multiple pathways. Their canonical function at the cellular level is to impede access of insulin-like growth factor (IGF)-1 and IGF-2 to their principal receptor IGF1R, but IGFBPs can also inhibit, or sometimes enhance, IGF1R signaling either through their own post-translational
-
Molecular and Clinical Spectrum of Primary Hyperparathyroidism. Endocr. Rev. (IF 22.0) Pub Date : 2023-09-15 Smita Jha,William F Simonds
Recent data suggest an increase in the overall incidence of parathyroid disorders, with primary hyperparathyroidism (PHPT) being the most prevalent parathyroid disorder. PHPT is associated with morbidities (fractures, kidney stones, chronic kidney disease) and increased risk of death. The symptoms of PHPT can be nonspecific, potentially delaying the diagnosis. Approximately 15% of patients with PHPT
-
Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention. Endocr. Rev. (IF 22.0) Pub Date : 2023-07-11 Alexia Carré,Federica Vecchio,Malin Flodström-Tullberg,Sylvaine You,Roberto Mallone
The evidence for an association between coxsackievirus B (CVB) infection, pancreatic islet autoimmunity, and clinical type 1 diabetes is increasing. Results from prospective cohorts and pancreas histopathology studies have provided a compelling case. However, the demonstration of a causal relationship is missing, and is likely to remain elusive until tested in humans by avoiding exposure to this candidate
-
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? Endocr. Rev. (IF 22.0) Pub Date : 2023-07-11 Rocio Garcia-Carbonero,Beatriz Anton-Pascual,Andrea Modrego,Maria Del Carmen Riesco-Martinez,Alberto Lens-Pardo,Carlos Carretero-Puche,Beatriz Rubio-Cuesta,Beatriz Soldevilla
Poorly differentiated gastroenteropancreatic neuroendocrine carcinomas are aggressive neoplasms of challenging clinical management. A small proportion of patients with early-stage disease may achieve long-term survival, but the majority of patients present with rapidly lethal metastatic disease. Current standard of care still follows the treatment paradigm of small cell lung cancer, a far more common
-
Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy. Endocr. Rev. (IF 22.0) Pub Date : 2023-07-11 Veronica Vella,Rosamaria Lappano,Eduardo Bonavita,Marcello Maggiolini,Robert Bryan Clarke,Antonino Belfiore,Ernestina Marianna De Francesco
In metabolic conditions such as obesity and diabetes, which are associated with deregulated signaling of the insulin/insulin-like growth factor system (IIGFs), inflammation plays a dominant role. In cancer, IIGFs is implicated in disease progression, particularly during obesity and diabetes; however, further mediators may act in concert with IIGFs to trigger meta-inflammation. The receptor for advanced
-
LGR4: A New Receptor Member in Endocrine and Metabolic Diseases. Endocr. Rev. (IF 22.0) Pub Date : 2023-07-11 Ningning Zhang,Mingyang Yuan,Jiqiu Wang
Classic hormone membrane receptors, such as leucine-rich repeat-containing G protein-coupled receptor (LGR) 1 (follicle-stimulating hormone receptor), LGR2 (luteinizing hormone receptor), and LGR3 (thyrotropin receptor), are crucial in endocrinology and metabolism, and the identification of new receptors can advance this field. LGR4 is a new member of this G protein-coupled receptor family and shows
-
Correction to: "The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty". Endocr. Rev. (IF 22.0) Pub Date : 2023-03-04